品系特征：

• 表达嵌合的CTLA-4；
• hCTLA-4的表达模式及调控是生理性的；
• 与配体的结合/相互作用几乎不受影响；
• 健全的鼠源免疫系统；
• mCTLA-4（胞外区）不表达，可避免交叉反应。

验证信息：

（1）hCTLA-4在T细胞上的表达情况

从WT和hCTLA-4小鼠上分离脾细胞，经αCD3激活后检测；

• hCTLA-4小鼠上，hCTLA-4在Tregs、CD4+和CD8+ T细胞上的表达情况与WT小鼠类似；

（2）hCTLA-4小鼠免疫细胞总数及分布情况

从WT和hCTLA-4小鼠上分离脾细胞；

• hCTLA-4小鼠脾细胞总细胞数以及免疫细胞分布情况与WT小鼠类似；

（3）体内药效评估

在WT和hCTLA-4小鼠上接种MC38肿瘤细胞系，对Ipilimumab（anti-hCTLA-4 ）和anti-mCTLA-4进行药效学评估；

• Ipilimumab（anti-hCTLA-4 ）延长了hCTLA-4荷瘤小鼠的生存期；

更多详细数据请联系我们：联系我们 - 基锘威 - genOway (my3w.com)

案例

1. Uncoupling toxicity from therapeutic efficacy: a case study on ATOR-1015
2. Uncoupling efficacy from toxicity: a case study on MEDI5752 

评论

1. CCX559 is a potent, orally-administered small molecule PD-L1 inhibitor that induces anti-tumor immunity 
2. A new promising family of small molecules regulating the PD-L1/PD-1 signaling pathway
3. An alternative approach to immunotherapy: A bispecific agonist
4. Relevant preclinical models to test T-cell engagers: The case of CD28
5. Uncoupling toxicity from therapeutic efficacy: the new challenge of immunotherapies 
6. Part 4: Humanized immune checkpoint mouse models for immuno-oncology studies
7. A VISTA on naive T cell fate
8. A new Nature report by Bristol-Myers Squibb provides new insights into VISTA biology and design of combination therapies
9. Immune checkpoint inhibitors: A strategy to tackle cancer? 

海报

1.  Anti-VISTA agents profiling: complementarity of BRGSF-HIS and hVISTA Knock-in as preclinical models for immunotherapies